Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,154 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Clear all
Recruiting Not applicable Interventional

Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs

NCT06042543
View directory record Official record
Conditions
Cervical Cancer, Screening
Interventions
Screening with HPV test
Diagnostic Test
Lead sponsor
International Agency for Research on Cancer
Other
Eligibility
25 Years to 49 Years · Female only
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting No phase listed Observational

Volume Outcome Relationships and Effects

NCT06343597
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2020 – 2028
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01266460
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
Interventions
Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

Trigger Point Injections in Anterior Cervical Surgery

NCT04640896
View directory record Official record
Conditions
Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions
Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Not applicable Interventional Results available

Cervical Pessary to Prevent Preterm Birth in Singleton Pregnancies With a Sonographically Measured Short Cervix

NCT02357394
View directory record Official record
Conditions
Premature Birth
Interventions
Arabin Pessary
Device
Lead sponsor
Gene Lee, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Kansas City, Kansas • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma

NCT05322135
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
18F-FSPG, 11C-Glutamine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 10:34 PM EDT
Not listed Not applicable Interventional

Efficacy and Safety of TORS for SCCA

NCT01819480
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, Supraglottic Squamous Cell Carcinoma
Interventions
Transoral robotic surgery
Procedure
Lead sponsor
Katherine L Fedder
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

NCT05229341
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Diagnostic Procedure, Electronic Health Record Review, Needle Biopsy
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed No phase listed Observational

Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis

NCT02140905
View directory record Official record
Conditions
Heart Failure, Kidney Disease
Interventions
Not listed
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
21 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 21, 2026, 10:34 PM EDT
Completed No phase listed Observational

Clinical Registry of Long-Term Dental Outcomes in Head and Neck Cancer Patients

NCT05325970
View directory record Official record
Conditions
Head and Neck Cancer, Dental Diseases, Osteoradionecrosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Farmington, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

NCT00215605
View directory record Official record
Conditions
Lymphoma, Cancer, Thyroid Carcinoma
Interventions
XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

NCT03504488
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions
CAB-ROR2-ADC, PD-1 inhibitor
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 3 Interventional

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting No phase listed Observational

Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain

NCT07639060
View directory record Official record
Conditions
Chronic Pain, PERIPHERAL NEUROPATHY, Occipital Neuralgia, Chronic Hip Pain, Hip Osteoarthritis, Knee Osteoarthritis, Spasticity, Chronic Low Back Pain, Lumbar Spondylosis, Cervical Spondylosis, Shoulder Arthritis, Causalgia, Chronic Pain Syndrome, Chronic Neck Pain
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Old Saybrook, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated No phase listed Interventional Results available

Intended Use Study of the BD SurePath Plus™ Pap

NCT01234480
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Uterine Cervical Cancer, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Papilloma
Interventions
BD SurePath Plus Pap test, BD SurePath Pap test, colposcopy with biopsy/ECC, HPV DNA test
Device · Procedure
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
5,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 21, 2026, 10:34 PM EDT
Completed No phase listed Observational

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

NCT01393483
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma
Interventions
serum and tissue mesothelin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer

NCT01843673
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
computed tomography, cone-beam computed tomography, radiography, electronic portal imaging, image-guided adaptive radiation therapy
Procedure · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

NCT04066894
View directory record Official record
Conditions
Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions
Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery
Procedure · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 10:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239
View directory record Official record
Conditions
Neoplasms
Interventions
BI 765179, Ezabenlimab, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:34 PM EDT